Searchable abstracts of presentations at key conferences in endocrinology

ea0022s21.2 | The cardiometabolic interface | ECE2010

Role of PPAR signalling in diabetic dyslipidemia

Staels Bart

Despite that statin treatment substantially reduces cardiovascular morbidity and mortality, many treated patients still experience a high residual risk. Statins lower LDL-cholesterol (LDL-C), with limited effects on other lipid parameters. A meta-analysis from 14 randomised trials conducted in high-risk patients reported that statin therapy is effective in reducing the proportional risk for major vascular events by 21% for each mmol/l lowering of LDL-C. However, on average 14%...

ea0015s37 | Inflammation and the adipocyte - integrated pathways that regulate disease risk | SFEBES2008

Nuclear receptors and regulation of inflammatory pathways

Staels Bart

Cardiovascular disease is significantly increased in patients with the metabolic syndrome and type 2 diabetes. A clustering of risk factors, including dyslipidemia, insulin resistance, hypertension, inflammation and coagulation disorders result in an increased risk for cardiovascular events in these patients. PPARs (Peroxisome Proliferator-Activated Receptors) and LXRs are ligand-activated transcription factors that control lipid and glucose metabolism, as well as the inflamma...